Dr Yada Kanjanapan

MBBS, FRACP
Medical Oncologist
Become a Patient

Dr Yada Kanjanapan is committed to delivering evidence-based care in collaboration with her surgical and radiation oncology colleagues as part of a multidisciplinary team.

Biography

Dr Yada Kanjanapan is an experienced medical oncologist at Icon Cancer Centre Canberra. She attended the University of Adelaide where she obtained a Bachelor of Medicine and Bachelor of Surgery (MBBS) and completed specialist oncology training at Canberra Hospital and Peter MacCallum Cancer Centre, Melbourne. Dr Kanjanapan subsequently completed a two-year clinical research fellowship in drug development, melanoma and gynaecological cancers at the Princess Margaret Cancer Centre in Toronto, Canada. She held a medical oncology position at Sydney’s Prince of Wales Hospital where she managed a wide range of solid tumour malignancies.

Since returning to her home town, Canberra, Dr Kanjanapan has been active in private practice and her role as a staff specialist at Canberra Hospital. She is currently an investigator in a number of clinical trials. Her research interest and expertise includes breast cancer, immunotherapy and developmental therapeutics, with a strong publication record.  In 2018, Dr Kanjanapan was a recipient of an American Society of Clinical Oncology (ASCO) Merit Award. She is also a clinical lecturer at the Australian National University; teaching and mentoring medical students in clinical skills and research.

Dr Kanjanapan’s clinical experience covers a broad range of solid tumour malignancies with special clinical interest in breast, gynaecological cancers and melanoma. She can converse in Chinese Mandarin and Thai, and looks forward to working with patients in their language.

Affiliations & Memberships

  • Australia and New Zealand Breast Cancer Trials Group (ANZBCTG)
  • Australia New Zealand Gynaecological Oncology Group (ANZGOG)
  • American Society of Clinical Oncology (ASCO)
  • Medical Oncology Group of Australia (MOGA)
  • Royal Australasian College of Physicians (RACP)

Special Interests

Dr Yada Kanjanapan accepts referrals for all cancer types, with a special clinical interest in:
  • Breast cancer
  • Gynaecological cancer
  • Melanoma

Icon Locations

Canberra View centre

Visiting Locations

  • Canberra Hospital

Publications

  • Impact of prior (neo)adjuvant trastuzumab exposure on the efficacy of HER2 targeted therapy for metastatic breast cancer. Y. Kanjanapan,  D. Tran, S.W. Lok, P.Gibbs, R. De Boer, B. Yeo, S. Greenberg, F. Barnett, L. Nott, G. Richardson, R. Wong, M. Nottage, I. Collins, J. Torres, J. Lombard, J. Johns, M. Harold & L. Malik. Breast Cancer Research and Treatment, 2020.

  • Hyperprogressive disease in early‐phase immunotherapy trials: Clinical predictors and association with immune‐related toxicities. Y. Kanjanapan, D. Day, L. Wang, H. Al‐Sawaihey, E. Abbas, A. Namini, L.L. Siu, A. Hansen, A.A. Razak, A. Spreafico, N. Leighl, A.M. Joshua, M.O. Butler, D. Hogg, M.A. Chappell, L. Soultani, K. Chow, S. Boujo & P.L. Bedard. Cancer, 2019; 125(8): 1341-1349.

  • Delayed immune-related adverse events in assessment for dose-limiting toxicity in early phase immunotherapy trials. Y. Kanjanapan, D. Day, M.O. Butler, L. Wang, A.M. Joshua, D. Hogg, N.B. Leighl, A.R. Abdul Razak, A. Hansen, S. Boujos, M. Chappell, K.Chow, B. Sherwin, L.A. Stayner, L. Soultani, A. Zambrana, L.L. Siu, L.Bedard & A. Spreafico. European Journal of Cancer; 2019; 107: 1-7.

  • Novel patterns of response under immunotherapy. Borcoman, Y. Kanjanapan, S. Champiat, S. Kato, V. Servois, R. Kurzrock, S. Goel, P. Bedard & C. Le Tourneau. Annals of Oncology, 2019; 30: 385-396.

  • Niraparib for the treatment of ovarian cancer. Y. Kanjanapan, S. Lheureux & A. Oza. Expert Opinion on Pharmacotherapy, 2017; 18(6): 631-640.

View all Doctors

Search